Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
Ended Project Grant Awarded Last action
- Award ID
- R21CA267394
- Recipient
-
Swedish Health Services UEI GZ5WW5GZY2A5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,248,256
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Washington, USA
Award details come from USAspending.gov.
Description
- Abstract
- Glioblastoma (GBM) is the most malignant type of brain tumor, with a median survival time of 15 months. Despite advances in cancer survival for many malignancies, GBM survival rates still remain low and have not significantly changed over the last 30 years, emphasizing the urgent need for new treatment options. One of the common hallmarks of cancer is splicing perturbations and alternatively spliced genes are an interesting new source for potential diagnostic biomarkers and therapeutic targets. Current methodologies to characterize splicing in tumors using mrna sequencing can only indicate that alternative exons are transcribed, but additional validation is needed to verify that these spliceforms produce functional proteins. Our preliminary results comparing paired tumor/normal samples indicate that alternative splicing in GBM affects many more genes than previously expected, both at the transcript and protein levels. Based on these data, we hypothesize that a set of alternatively spliced genes are involved in tumor initiation and GBM pathogenesis. In this proposal, we will use a combination of precision medicine approaches to detect and quantify tumor-specific alternative splicing events in gbms. We will verify that these events produce distinct proteoforms using splicing-aware proteogenomics experiments. Finally, we will functionally characterize differentially expressed splice isoform candidates for their effects on growth, apoptosis, and invasion in patient-derived glioma stem cells. If successful, this work will lead to new understanding of the biological impact of novel GBM proteoforms, and potentially lead to novel approaches to treatment of GBM based on unique tumor antigens and molecular pathways.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$5,540 | |
| Amendment | $11,504 | |
| Amendment | $207,100 | |
| Amendment | $207,100 | |
| Amendment | $207,023 | |
| Amendment | $207,023 | |
| Amendment | $207,023 | |
| Original award | $207,023 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Ohio State University | $72,831 |
Quick answers
Who received award R21CA267394?
R21CA267394 was awarded to Swedish Health Services by National Cancer Institute (National Institutes of Health) on January 1, 2023.
How much is award R21CA267394 worth?
$1,248,256 has been obligated on R21CA267394.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award